1. Others
  2. Androgen Receptor
  3. RD162

RD162 

Cat. No.: HY-111145
Handling Instructions

RD162, a diarylthiohydantoin, is an orally active non-steroidal antiandrogen (NSAA). RD162 specifically binds to androgen receptor (AR). RD162 induces tumor regression in mouse models of castration-resistant human prostate cancer.

For research use only. We do not sell to patients.

RD162 Chemical Structure

RD162 Chemical Structure

CAS No. : 915087-27-3

Size Stock
100 mg   Get quote  
250 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

RD162, a diarylthiohydantoin, is an orally active non-steroidal antiandrogen (NSAA). RD162 specifically binds to androgen receptor (AR). RD162 induces tumor regression in mouse models of castration-resistant human prostate cancer[1].

In Vitro

RD162 (1-10 μM; 4 days) suppresses growth and induces apoptosis in the human prostate cancer cell line VCaP which has endogenous AR gene amplification[1].
RD162 has little to no binding to the progesterone, estrogen or glucocorticoid receptors in an in vitro fluorescence polarization assay[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: VCaP cells
Concentration: 1, 10 μM
Incubation Time: 4 days
Result: Suppressed cell growth.
In Vivo

RD162 (10 mg/kg; oral gavage; daily; for 28 days) causes all tumors regressed[1].
RD162 (0.1, 1, 10 mg/kg; oral gavage; daily; for 5 days) consistently reduces luciferase activity with 10 mg/kg/day human LNCaP/AR xenografts grown in castrated male mice whereas lower doses of 0.1 and 1.0 mg/kg/day has minimal effect. RD162 substantially reduces cellular proliferation after 5 days[1].
RD162 (20 mg/kg; gavage) is ∼50 percent bioavailable after oral delivery with a serum half-life of about 30 hours[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Castrate male mice bearing LNCaP/AR xenografts[1]
Dosage: 10 mg/kg
Administration: Oral gavage; daily; for 28 days
Result: Caused all tumors regressed.
Animal Model: Male mice[1]
Dosage: 20 mg/kg (Pharmacokinetic Analysis)
Administration: Oral gavage (in 0.5% hydroxy-methyl-propyl-cellulose)
Result: Had ∼50 percent bioavailable after oral delivery with a serum half-life of about 30 hours.
Molecular Weight

476.45

Formula

C₂₂H₁₆F₄N₄O₂S

CAS No.
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
RD162
Cat. No.:
HY-111145
Quantity:
MCE Japan Authorized Agent: